Through translation of novel cell-based immunotherapies, the CoE CIT will facilitate early and affordable access of these practice-changing therapies for cancer patients in Australia and the wider Asia-Pacific region. Development of, and access to these therapies will come from increased focus and capacity of three avenues within the centre:
Building increased capabilities and capacities to advance cancer care
The Centre of Excellence in Cellular Immunotherapy is funded by a co-investment from the Federal Government, Cell Therapies Pty Ltd & the Peter MacCallum Cancer Foundation. This capital funding has been used to increase capabilities over CoE CIT's 3 pillars of excellence:
- Translational Research
- Manufacturing
- Clinical Research.
The CoE CIT is supported by partners in various health sectors who, in total, enable the centre to provide access to innovative patient care.
Goals of the Centre of Excellence in Cellular Immunotherapy
-
Increase the capability of clinical trials, building on Peter Mac’s current trials in adoptive immunotherapy.
-
Create a new Australian bio-manufacturing industry centred in Melbourne by identifying and supporting new research and development.
-
Increase capital investment for the development of a national centre that will provide standard of care and advance novel cellular immunotherapy treatments.
-
Create commercial opportunities for innovative Australian research, based on protecting new IP (Intellectual Property).